Resources
Welcome to the Adenoscan resources section. This is the Online Case Library Web page. For other resources, click on a link in the navigation bar above.

Online Case Library
The Adenoscan Online Case Library comprises an ongoing series of interactive educational cases featuring peer-to-peer case presentations that address various topics in myocardial perfusion imaging (MPI) and the utility of Adenoscan. These cases give you the educational opportunity to read nuclear images, formulate a clinical diagnosis or prognosis, and compare your interpretations with those of the author and your colleagues. Check back often, as new case studies will be added in the future.

Note: These case studies represent the opinions of their respective authors and do not necessarily reflect the opinions of Astellas Pharma US, Inc. In no event will Astellas Pharma US, Inc., be liable for any decision made or action taken in reliance upon the information provided in these case studies.

	James A. Arrighi, MD Brian G. Abbott, MD Assessment of Cardiac Risk in an Asymptomatic Diabetic Patient
	Olakunle Akinboboye, MD Myocardial Perfusion Imaging in a Middle-Aged African American Woman With Dyspnea
	James A. Arrighi, MD Brian G. Abbott, MD Myocardial Perfusion Imaging in a Diabetic Woman With Atypical Chest Pain
	Martha Gulati, MD Coronary Artery Disease in a Middle-Aged Woman With Rheumatoid Arthritis

IMPORTANT SAFETY INFORMATION

Intravenous Adenoscan^® (adenosine injection) is indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately.

Adenoscan is contraindicated in patients with 2nd- or 3rd-degree AV block, sinus node disease, and known or suspected bronchoconstrictive or bronchospastic lung disease.

Approximately 2.6% and 0.8% of patients developed second- and third-degree AV block, respectively. All episodes of AV block have been asymptomatic, transient, and did not require intervention; less than 1% required termination of adenosine infusion.

Fatal cardiac arrest, sustained ventricular tachycardia (requiring resuscitation), and nonfatal myocardial infarction have been reported coincident with Adenoscan infusion. Patients with unstable angina may be at greater risk.

Side effects that were seen most often included flushing (44%), chest discomfort (40%), and dyspnea (28%). Side effects usually resolve quickly when infusion is terminated and generally do not interfere with test results.

Despite adenosine’s short half-life, 10.6% of the side effects started several hours after the infusion terminated, and 8.4% of the side effects that began during the infusion persisted for up to 24 hours after infusion. In many cases, it is not possible to know whether these late adverse events are the result of Adenoscan infusion.

Please see full prescribing information.